CSIMarket


Roivant Sciences Ltd   (ROIV)
Other Ticker:  
 

Roivant Sciences Ltd

ROIV's Fundamental analysis








Looking into Roivant Sciences Ltd growth rates, revenue grew by 117.8 % in III. Quarter 2023 from the same quarter a year ago. Ranking at No. 433

Major Pharmaceutical Preparations industry recorded deterioration of revenues by

Roivant Sciences Ltd realized net income compared to net loss a year ago in III. Quarter 2023

More on ROIV's Growth


Roivant Sciences Ltd
current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.

Roivant Sciences Ltd PEG ratio is at -0.01 Company is currently trading with Price to Cash flow multiple of 1.7 in trailing twelve-month period.
Company
1.99
PE TTM   
Industry
360.97
PE TTM    
Company's Price to Sales ratio is at 70.99.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.34.


More on ROIV's Valuation
 
 Total Debt (Millions $) 449
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ -
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) -
 Tangible Book Value (Per Share $) 7.62

Roivant Sciences Ltd
current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.

Roivant Sciences Ltd PEG ratio is at -0.01 Company is currently trading with Price to Cash flow multiple of 1.7 in trailing twelve-month period.
Company
1.99
PE TTM   
Industry
360.97
PE TTM    
Company's Price to Sales ratio is at 70.99.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.34.

Roivant Sciences Ltd Price to Book Ratio is at 1.33 lower than Indusry Avg. of 1523.92. and higher than S&P 500 Avg. of 0.01

More on ROIV's Valuation

  Market Capitalization (Millions $) 8,749
  Shares Outstanding (Millions) 844
  Employees -
  Revenues (TTM) (Millions $) 123
  Net Income (TTM) (Millions $) 4,353
  Cash Flow (TTM) (Millions $) 5,144
  Capital Exp. (TTM) (Millions $) -3
  Total Debt (Millions $) 449
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ -
  Net Income/Employee(TTM) $ -
  Receivable Turnover Ratio (TTM) -
  Tangible Book Value (Per Share $) 7.62

  Market Capitalization (Millions $) 8,749
  Shares Outstanding (Millions) 844
  Employees -
  Revenues (TTM) (Millions $) 123
  Net Income (TTM) (Millions $) 4,353
  Cash Flow (TTM) (Millions $) 5,144
  Capital Exp. (TTM) (Millions $) -3


    ROIV's Profitability Comparisons
Roivant Sciences Ltd achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2023 to 13626.5 %.

Roivant Sciences Ltd net profit margin of 13658.23 % is currently ranking no. 1 in Major Pharmaceutical Preparations industry, ranking no. 1 in Healthcare sector and number 8 in S&P 500.





  Ratio
   Capital Ratio (MRQ) 27.79
  Total Debt to Equity (MRQ) 0.07
  Tangible Leverage Ratio (MRQ) 0.19
  Asset Turnover Ratio (TTM) 0.04
  Inventory Turnover Ratio (TTM) -



Roivant Sciences Ltd achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2023 to 13626.5 %.

Roivant Sciences Ltd net profit margin of 13658.23 % is currently ranking no. 1 in Major Pharmaceutical Preparations industry, ranking no. 1 in Healthcare sector and number 8 in S&P 500.

More on ROIV's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com